Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1

This study has been completed.
Yale University
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: September 20, 1999
Last updated: August 16, 2005
Last verified: December 2002
The purpose of this study is to compare the clinical efficacy of maintenance on low and high doses of buprenorphine with methadone for cocaine abusing opiate addicts.

Condition Intervention Phase
Cocaine-Related Disorders
Opioid-Related Disorders
Substance-Related Disorders
Drug: Buprenorphine
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Depression
  • Withdrawal symptoms
  • Opioid and cocaine use
  • Social and psychological functioning
  • AIDS risk behavior

Estimated Enrollment: 0

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000216

United States, Connecticut
APT Residential Services Division
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Yale University
Principal Investigator: Richard Schottenfeld, M.D. Yale University
  More Information

Publications: Identifier: NCT00000216     History of Changes
Other Study ID Numbers: NIDA-06266-1  R01-06266-1 
Study First Received: September 20, 1999
Last Updated: August 16, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Opioid-Related Disorders
Cocaine-Related Disorders
Substance-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists
Anesthetics, Local
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents processed this record on October 25, 2016